According to the Zhitong Finance APP, AIRDOC-B (02251) has risen over 12%, and as of the time of writing, it is up 11.13%, trading at HKD 12.78, with a transaction volume of HKD 1.4026 million.
In terms of news, on February 7th, Airdoc announced that its independently developed Wanyu Medical Large Model has completed a major upgrade and has integrated the DeepSeek R1 model. It is reported that the company laid out the Airdoc Wanyu Medical Large Model in July 2024 and upgraded to integrate the DeepSeek R1 large model in February 2025, significantly improving clinical diagnostic efficiency and accuracy, providing more professional report interpretation and a more personalized patient health management experience.
CITIC Construction Investment pointed out that AIRDOC is the first company in China to obtain the NMPA-approved Class III auxiliary diagnostic registration certificate for artificial intelligence. As a leader and pioneer in the global field of artificial intelligence retinal image recognition, the company is committed to using artificial intelligence research technology to provide integrated AI solutions for chronic disease early screening management and eye health. AIRDOC's main product, Airdoc-AIFUNDUS 1.0, has received the first Class III medical device certificate for AI-assisted diagnosis of fundus from the National Medical Products Administration, aimed at assisting in the diagnosis of diabetic retinopathy to help doctors make medical diagnoses

02251

AIRDOC-B rose over 12%, as of the time of writing, it increased by 11.13%, priced at HKD 12.78, with a transaction volume of HKD 1.4026 million. In terms of news, on February 7th, AIRDOC announced that its self-developed WanYu Medical Large Model has completed a significant upgrade and has integrated the DeepSeek R1 model. It is reported that the company laid out the AIRDOC WanYu Medical Large Model in July 2024 and upgraded to integrate the DeepSeek R1 large model in February 2025, significantly improving clinical diagnosis efficiency and accuracy, providing more professional report interpretations and a more personalized patient health management experience. CITIC Construction Investment pointed out that AIRDOC is the first company in China to obtain the NMPA-approved Class III AI-assisted diagnostic registration certificate. As a leader and pioneer in the global AI retinal image recognition field, the company is committed to using AI research technology to provide integrated AI solutions for chronic disease early screening management and eye health diagnosis and treatment. AIRDOC's main product, Airdoc-AIFUNDUS 1.0, has obtained the first Class III medical device certificate for AI-assisted diagnosis of fundus from the National Medical Products Administration, aimed at assisting in the diagnosis of diabetic retinopathy to help doctors make medical diagnoses